Mitochondrial therapeutic agents
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsOmar KHDOUR, Sidney HECHT, Jun LIU, Indrajit BANDYOPADHYAY
Life of this patent
Estimating the term…
Abstract
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 has any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as cytoprotective agents.
Claims21
1-27. (canceled)
A compound of formula:
- or a salt thereof.
A method of quantifying lipid peroxidation in a FRDA lymphocyte comprising the steps of treating the lymphocyte with a compound of formula I:
- or a salt thereof and an oxidative-sensitive fluorescent probe, followed by measuring the change in fluorescence of the probe, and quantifying lipid peroxidation of the lymphocyte using the measured change in fluorescence, wherein, R1 is C2-C20 alkyl optionally substituted with one or more halo.
A pharmaceutical composition in the form of a tablet, capsule, injection or aerosol, comprising a compound of formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein, R1 is C2-C20 alkyl optionally substituted with one or more halo;
- and
- wherein:
- (a) the tablet comprises 100 mg or 20 mg of the compound of formula I or a pharmaceutically acceptable salt thereof;
- (b) the capsule comprises 10 mg of the compound of formula I or a pharmaceutically acceptable salt thereof;
- (c) the injection comprises 1 mg/ml or 10 mg/ml of the compound of formula I or a pharmaceutically acceptable salt thereof;
- and
- (d) the aerosol comprises 20 mg/can of the compound of formula I or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.